152400 - AstraZeneca COVID-19 vaccine and Guillain- Barr acute accent e Syndrome in Tasmania.pdf (5.67 MB)
AstraZeneca COVID-19 vaccine and Guillain- Barr acute accent e Syndrome in Tasmania: a causal link?
journal contribution
posted on 2023-05-21, 12:02 authored by Oo, Wai M, Giri, Pradeep, Aaron de SouzaAaron de SouzaThe emergence of the coronavirus 2019 (COVID-19) pandemic has presented an unprecedented global challenge. Vaccines against COVID have been developed to date. Covid-19 has been linked with the development of Guillain-Barre Syndrome (GBS), a rare immune-mediated demyelinating neuropathy. We report three cases of Guillain-Barre Syndrome and one case of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), presenting to a Tasmanian hospital, and review 15 other reported cases and discuss likely immunopathology. Nearly all reported cases of post-COVID-19 vacciation inflammatory demyelinating polyneuropathy are linked to AstraZeneca vaccination and a variant with bifacial weakness is the most reported form of GBS globally.
History
Publication title
Journal of NeuroimmunologyVolume
360Article number
360:577719Number
360:577719Pagination
1-5ISSN
0165-5728Department/School
Tasmanian School of MedicinePublisher
Elsevier/North-HollandPlace of publication
AmsterdamRights statement
Crown Copyright © 2021 Published by Elsevier B.V. All rights reserved.Repository Status
- Open